Cargando…
The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study
Background: The outcome of patients with intermediate stage hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) remains poor. Search for a more effective therapy is still necessary. Objective: This study aimed to investigate the effect of combining TACE with Kang’ai (KA)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041935/ https://www.ncbi.nlm.nih.gov/pubmed/29108428 http://dx.doi.org/10.1177/1534735417734913 |
_version_ | 1783339074341306368 |
---|---|
author | Wan, Yue-Meng Li, Yu-Hua Xu, Zhi-Yuan Wu, Hua-Mei Xu, Ying Yang, Mei Wu, Xi-Nan |
author_facet | Wan, Yue-Meng Li, Yu-Hua Xu, Zhi-Yuan Wu, Hua-Mei Xu, Ying Yang, Mei Wu, Xi-Nan |
author_sort | Wan, Yue-Meng |
collection | PubMed |
description | Background: The outcome of patients with intermediate stage hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) remains poor. Search for a more effective therapy is still necessary. Objective: This study aimed to investigate the effect of combining TACE with Kang’ai (KA) injection for treating patients with intermediate stage HCC. Methods: A total of 89 patients with intermediate stage HCC were enrolled and divided into TACE +KA group (n = 48) receiving repeated TACE plus KA injection, and TACE group (n = 41) receiving repeated TACE alone. All patients were prospectively studied. Primary endpoints were overall survival (OS) and time to radiologic progression (TTP). Results: The TACE + KA group had significantly longer median OS (27.0 vs 21.0 months, P = .038) and TTP (12.0 vs 10.0 months, P = .028) than TACE group. The 1-, 2-, and 3-year OS rates in the TACE + KA group were markedly higher than in TACE group (88.5%, 58.8%, and 20.8% vs 81.3%, 44.9%, and 6.7%, respectively, P = .038), while the 1- and 2-year TTP rates in the TACE + KA group were significantly lower than in TACE group (49.3% and 86.9% vs 75.3% and 100%, P = .028). TACE + KA group displayed significantly lower incidences of intrahepatic and extrahepatic metastases, as well as postembolization syndrome than TACE group (P < .05). Multivariate analyses revealed group (P = .023), maximum tumor size (P = .019), and tumor number (P = .034) as significant predictors for OS, and group (P = .046), maximum tumor size (P = .002) and α-fetoprotein level (P = .020) as significant predictors for TTP. Both TACE and KA injection were well tolerated. Conclusion: TACE plus KA injection is more effective than TACE alone for treating patients with intermediate stage HCC in this nonrandomized study. Further research is warranted. |
format | Online Article Text |
id | pubmed-6041935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60419352018-07-16 The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study Wan, Yue-Meng Li, Yu-Hua Xu, Zhi-Yuan Wu, Hua-Mei Xu, Ying Yang, Mei Wu, Xi-Nan Integr Cancer Ther Research Articles Background: The outcome of patients with intermediate stage hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) remains poor. Search for a more effective therapy is still necessary. Objective: This study aimed to investigate the effect of combining TACE with Kang’ai (KA) injection for treating patients with intermediate stage HCC. Methods: A total of 89 patients with intermediate stage HCC were enrolled and divided into TACE +KA group (n = 48) receiving repeated TACE plus KA injection, and TACE group (n = 41) receiving repeated TACE alone. All patients were prospectively studied. Primary endpoints were overall survival (OS) and time to radiologic progression (TTP). Results: The TACE + KA group had significantly longer median OS (27.0 vs 21.0 months, P = .038) and TTP (12.0 vs 10.0 months, P = .028) than TACE group. The 1-, 2-, and 3-year OS rates in the TACE + KA group were markedly higher than in TACE group (88.5%, 58.8%, and 20.8% vs 81.3%, 44.9%, and 6.7%, respectively, P = .038), while the 1- and 2-year TTP rates in the TACE + KA group were significantly lower than in TACE group (49.3% and 86.9% vs 75.3% and 100%, P = .028). TACE + KA group displayed significantly lower incidences of intrahepatic and extrahepatic metastases, as well as postembolization syndrome than TACE group (P < .05). Multivariate analyses revealed group (P = .023), maximum tumor size (P = .019), and tumor number (P = .034) as significant predictors for OS, and group (P = .046), maximum tumor size (P = .002) and α-fetoprotein level (P = .020) as significant predictors for TTP. Both TACE and KA injection were well tolerated. Conclusion: TACE plus KA injection is more effective than TACE alone for treating patients with intermediate stage HCC in this nonrandomized study. Further research is warranted. SAGE Publications 2017-11-07 /pmc/articles/PMC6041935/ /pubmed/29108428 http://dx.doi.org/10.1177/1534735417734913 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Articles Wan, Yue-Meng Li, Yu-Hua Xu, Zhi-Yuan Wu, Hua-Mei Xu, Ying Yang, Mei Wu, Xi-Nan The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title | The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title_full | The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title_fullStr | The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title_full_unstemmed | The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title_short | The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study |
title_sort | effect of transarterial chemoembolization in combination with kang’ai injection on patients with intermediate stage hepatocellular carcinoma: a prospective study |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041935/ https://www.ncbi.nlm.nih.gov/pubmed/29108428 http://dx.doi.org/10.1177/1534735417734913 |
work_keys_str_mv | AT wanyuemeng theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT liyuhua theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT xuzhiyuan theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT wuhuamei theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT xuying theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT yangmei theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT wuxinan theeffectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT wanyuemeng effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT liyuhua effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT xuzhiyuan effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT wuhuamei effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT xuying effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT yangmei effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy AT wuxinan effectoftransarterialchemoembolizationincombinationwithkangaiinjectiononpatientswithintermediatestagehepatocellularcarcinomaaprospectivestudy |